MX2009001014A - Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie. - Google Patents
Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.Info
- Publication number
- MX2009001014A MX2009001014A MX2009001014A MX2009001014A MX2009001014A MX 2009001014 A MX2009001014 A MX 2009001014A MX 2009001014 A MX2009001014 A MX 2009001014A MX 2009001014 A MX2009001014 A MX 2009001014A MX 2009001014 A MX2009001014 A MX 2009001014A
- Authority
- MX
- Mexico
- Prior art keywords
- surface expression
- mediation
- cytotoxicity
- cdmab
- primary
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere al diagnóstico y tratamiento de enfermedades cancerosas, particularmente a la mediación de citotoxicidad de células tumorales humanas primarias y metastáticas, y mucho más particularmente al uso de un anticuerpo monoclonal aislado o un anticuerpos modificadores de enfermedad cancerosa (CDMAB) de ellas, opcionalmente en combinación con uno o más agentes quimioterapéuticos, como un medio para iniciar la respuesta citotóxica en dichos tumores en humanos, por ejemplo, cualquier sitio de tumor primario o metastásico que surge de hepatocitos. La invención se refiere además a análisis de fijación que utilizan los CDMAB de la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/493,407 US7534429B2 (en) | 2000-11-29 | 2006-07-26 | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
PCT/CA2007/001317 WO2008011710A1 (en) | 2006-07-26 | 2007-07-24 | Cytotoxicity mediation of cells evidencing surface expression of cd63 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009001014A true MX2009001014A (es) | 2009-06-22 |
Family
ID=38981088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009001014A MX2009001014A (es) | 2006-07-26 | 2007-07-24 | Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie. |
Country Status (10)
Country | Link |
---|---|
US (1) | US7534429B2 (es) |
EP (1) | EP2073851A4 (es) |
JP (1) | JP2009544629A (es) |
KR (1) | KR20090057970A (es) |
CN (1) | CN101553259A (es) |
AU (1) | AU2007278791A1 (es) |
BR (1) | BRPI0715541A2 (es) |
CA (1) | CA2666464A1 (es) |
MX (1) | MX2009001014A (es) |
WO (1) | WO2008011710A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048416B2 (en) * | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7009040B2 (en) * | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7175846B2 (en) * | 2003-01-21 | 2007-02-13 | Arius Research Inc. | Cancerous disease modifying antibodies |
ES2687974T3 (es) * | 2012-03-14 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Moléculas multiespecíficas de unión a antígeno y uso de las mismas |
EP4003402A4 (en) * | 2019-07-24 | 2023-11-22 | Agonox, Inc. | CD63 AGONIST-ASSOCIATED METHODS AND COMPOSITIONS |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4253880A (en) | 1977-09-23 | 1981-03-03 | U.S. Philips Corporation | Device for the conversion of solar energy into electrical energy |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
MA20406A1 (fr) | 1985-04-09 | 1985-12-31 | Majeste Hassan Ii Roi Du Maroc | Dispositif pour la detection, l'etude et la surveillance de maladies, notamment cardiaques, se traduisant par des manifestations electriquement enregistrables |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
NZ222509A (en) | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
US5296348A (en) | 1989-05-16 | 1994-03-22 | The Wistar Institute Of Anatomy And Biology | Methods for screening monoclonal antibodies for therapeutic use |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
DE69229254T2 (de) | 1991-10-30 | 1999-09-23 | Idemitsu Kosan Co | Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
IL105008A0 (en) | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
ATE244888T1 (de) | 1993-02-05 | 2003-07-15 | Epigen Inc | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
EP1018518A2 (en) | 1994-06-24 | 2000-07-12 | Vladimir P. Torchilin | Use of autoantibodies for tumor therapy and prophylaxis |
US6130276A (en) | 1995-06-07 | 2000-10-10 | Owens Corning Fiberglas Technology, Inc. | Method of reducing fumes from a vessel of molten asphalt |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6783961B1 (en) | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
US6245898B1 (en) | 1998-06-15 | 2001-06-12 | The Research Foundation Of State University Of New York | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
DE19832998A1 (de) | 1998-07-22 | 2000-02-03 | Siemens Ag | Verfahren zur Ermittlung von in einem kontinuierlichen Datenstrom enthaltenen Datenpaketen |
EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
US6068823A (en) | 1999-01-15 | 2000-05-30 | The University Of Houston System | Process for the benign direct fixation and conversion of nitrogen oxides |
CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
US7256271B2 (en) | 2003-01-21 | 2007-08-14 | Arius Research Inc. | Cancerous disease modifying antibodies |
US6657048B2 (en) | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US20040105816A1 (en) | 1999-10-08 | 2004-06-03 | Young David S. F. | Cancerous disease modifying antibodies |
US20020102638A1 (en) | 2000-01-31 | 2002-08-01 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
AU2001253140A1 (en) | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
CN1326951A (zh) | 2000-06-05 | 2001-12-19 | 上海博德基因开发有限公司 | 一种新的多肽——人cd63抗原15.07和编码这种多肽的多核苷酸 |
CN1326962A (zh) | 2000-06-05 | 2001-12-19 | 上海博德基因开发有限公司 | 一种新的多肽——人cd63抗原14.63和编码这种多肽的多核苷酸 |
WO2002000677A1 (en) | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
CN1351054A (zh) | 2000-10-26 | 2002-05-29 | 上海博德基因开发有限公司 | 一种新的多肽——人cd63抗原11.11和编码这种多肽的多核苷酸 |
US7431923B2 (en) | 2005-01-03 | 2008-10-07 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7009040B2 (en) | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US20060210474A1 (en) | 2000-11-29 | 2006-09-21 | Young David S | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
CN1364803A (zh) | 2001-01-10 | 2002-08-21 | 上海博德基因开发有限公司 | 一种新的多肽——人cd63抗原56.87和编码这种多肽的多核苷酸 |
US20030055220A1 (en) | 2001-01-12 | 2003-03-20 | Pierre Legrain | Protein-protein interactions between Shigella flexneri polypeptides and mammalian polypeptides |
US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
WO2002086069A2 (en) | 2001-04-20 | 2002-10-31 | Incyte Genomics, Inc. | Secreted proteins |
US7490541B2 (en) | 2001-07-09 | 2009-02-17 | Matsushita Electric Industrial, Co., Ltd. | Compressor |
EP1478772A2 (en) | 2001-08-14 | 2004-11-24 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
KR101008758B1 (ko) | 2001-09-18 | 2011-01-14 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
KR100623128B1 (ko) | 2002-01-02 | 2006-09-14 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
AU2003210266A1 (en) | 2002-02-14 | 2003-09-04 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
WO2003070902A2 (en) | 2002-02-20 | 2003-08-28 | Incyte Corporation | Receptors and membrane-associated proteins |
WO2003086456A2 (en) | 2002-04-05 | 2003-10-23 | Arius Research, Inc. | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer |
MXPA04010092A (es) | 2002-04-16 | 2004-12-13 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
JP2006515747A (ja) | 2002-11-01 | 2006-06-08 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
-
2006
- 2006-07-26 US US11/493,407 patent/US7534429B2/en not_active Expired - Fee Related
-
2007
- 2007-07-24 JP JP2009521073A patent/JP2009544629A/ja active Pending
- 2007-07-24 KR KR1020097001776A patent/KR20090057970A/ko not_active Application Discontinuation
- 2007-07-24 EP EP07784984A patent/EP2073851A4/en not_active Withdrawn
- 2007-07-24 AU AU2007278791A patent/AU2007278791A1/en not_active Abandoned
- 2007-07-24 MX MX2009001014A patent/MX2009001014A/es not_active Application Discontinuation
- 2007-07-24 CN CNA2007800306513A patent/CN101553259A/zh active Pending
- 2007-07-24 WO PCT/CA2007/001317 patent/WO2008011710A1/en active Application Filing
- 2007-07-24 BR BRPI0715541A patent/BRPI0715541A2/pt not_active IP Right Cessation
- 2007-07-24 CA CA002666464A patent/CA2666464A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2073851A4 (en) | 2010-04-21 |
JP2009544629A (ja) | 2009-12-17 |
EP2073851A1 (en) | 2009-07-01 |
WO2008011710A8 (en) | 2009-04-30 |
CN101553259A (zh) | 2009-10-07 |
CA2666464A1 (en) | 2008-01-31 |
KR20090057970A (ko) | 2009-06-08 |
BRPI0715541A2 (pt) | 2019-09-24 |
US20060269481A1 (en) | 2006-11-30 |
AU2007278791A1 (en) | 2008-01-31 |
WO2008011710A1 (en) | 2008-01-31 |
US7534429B2 (en) | 2009-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1732602A4 (en) | CYTOTOXIC MEDIATION OF CELLS WITH SUPERFICIAL EXPRESSION OF MCSP | |
HK1175846A1 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd44 cd44 | |
TW200731987A (en) | Cytotoxicity mediation of cells evidencing surface expression of CD44 | |
GB2449044A (en) | Cytotoxicity mediation of cells evidencing surface expression of cd63 | |
UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
TW200637875A (en) | Cytotoxicity mediation of cells evidencing surface expression of CD63 | |
PL2097453T3 (pl) | Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II) | |
IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
HK1082200A1 (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
WO2005062977A3 (en) | Prostate cancer specific internalizing human antibodies | |
MY147257A (en) | Polypeptides and antibodies | |
MX2009009926A (es) | Anticuerpo tumor-especifico humano monoclonal. | |
UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
EP2287194A3 (en) | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth | |
WO2006110745A3 (en) | Conjugated anti-psma antibodies | |
WO2007075921A3 (en) | De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy | |
EP3450459A3 (en) | Anti-cdh3 antibodies and uses thereof | |
MX2009001014A (es) | Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie. | |
WO2006029220A3 (en) | Combination therapy with anti-ctla4 and anti-4-1bb antibodies | |
EA200970884A1 (ru) | Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18 | |
WO2009023955A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd9 | |
WO2008137733A3 (en) | Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |